EDP167 vs SYH2070

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: ANGPTL3 · full Atherosclerotic Cardiovascular Disease pipeline

EDP167

Developed by Eddingpharm (Zhuhai) Co., Ltd. and partners

Phase 2 in Atherosclerotic Cardiovascular DiseaseRNAi (siRNA)
Weak signal

NCT07412080 · Phase 1 · completed

Participants were randomized to active drug or placebo with full blinding maintained, but the primary endpoint is safety and tolerability rather than a lipid or cardiovascular outcome, and results are not yet posted, so its eventual finding is unknown. Its registered primary outcome on ClinicalTrials.gov is "To evaluate the safety and tolerability of a single subcutaneous injection of EDP167 in adult subjects.". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: November 2027 · NCT07799129 (registry estimate)

No aligned efficacy figure on record for this race.

SYH2070

Developed by CSPC Pharmaceutical Group

Phase 2 in Atherosclerotic Cardiovascular DiseaseRNAi (siRNA)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: April 2027 · NCT07695597 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEDP167SYH2070
LDL-C, % change—Not reported—Not reported
Non-HDL-C, % change—Not reported—Not reported
ApoB, % change—Not reported—Not reported
Lp(a), % change—Not reported—Not reported
3-point MACE (% with event)—Not reported—Not reported

LDL-C, % change

EDP167
—Not reported
SYH2070
—Not reported

Non-HDL-C, % change

EDP167
—Not reported
SYH2070
—Not reported

ApoB, % change

EDP167
—Not reported
SYH2070
—Not reported

Lp(a), % change

EDP167
—Not reported
SYH2070
—Not reported

3-point MACE (% with event)

EDP167
—Not reported
SYH2070
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

EDP167: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.

SYH2070: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: EDP167's landscape · SYH2070's landscape